Journal Information
Vol. 19. Issue 9.
Pages 495-499 (November 2023)
Share
Share
Download PDF
More article options
Vol. 19. Issue 9.
Pages 495-499 (November 2023)
Brief Report
Liver fibrosis 4 score: Use in the evaluation of non-alcoholic fatty liver disease in patients with psoriatic arthritis
Índice de fibrosis hepática 4: uso en la evaluación de la enfermedad del hígado graso no alcohólico en pacientes con artritis psoriásica
Carlota Iñiguez Ubiagaa, Carlos García Porrúaa,
Corresponding author
carlos.garcia.porrua@sergas.es

Corresponding author.
, José Antonio Pinto Tasendeb, Lorena Paula Iñiguez Ubiagac, Amalia Sánchez-Andrade Fernandeza
a Rheumatology Department, University Hospital Lucus Augusti, Lugo, Spain
b Rheumatology Department, University Hospital Complex of A Coruña, A Coruña, Spain
c Centro de Salud Monte Alto, University Hospital Complex of A Coruña, A Coruña, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Descriptive analysis of the demographic variables.
Table 2. Relationship between FIB4 and ultrasound and clinical characteristics of the patients. Bivariate analysis.
Show moreShow less
Abstract
Objectives

To describe the prevalence of non-alcoholic fatty liver disease (NAFLD), the association between FIB4 and ultrasound findings, and the clinical characteristics of psoriatic arthritis patients.

Material and methods

We carried out an observational cross-sectional study of patients seen in the outpatient clinic from January 1st, 2020, to November 30th, 2020, with psoriatic arthritis.

Results

Of the 90 patients studied, the prevalence of NAFLD was 56.67%. FIB4 presents an association with ultrasound findings (p = .030), the absence of enthesitis (p = .036), and longer duration of disease (Rho .213 p = .042). It also presents an association with hypertension (p = .027) and alcohol consumption (p = .021). However, biological treatment can be considered as a protective factor (p = .005). FIB4 acts as a NAFLD predictor with 69.2% sensitivity and 70.4% specificity.

Conclusions

The prevalence of NAFLD was higher in our sample than in the standard population. FIB4 index may be useful in screening for silent liver damage in psoriatic arthritis in clinical practice.

Keywords:
Arthritis
Non-alcoholic fatty liver disease
NAFLD
Psoriasis
Psoriatic arthritis
Inflammation
Liver disease
Cirrhosis
Fibrosis
FIB4
Obesity
Treatment
Anti TNF alfa inhibitors
High blood pressure
Diabetes mellitus type 2
Resumen
Objetivos

Describir la prevalencia de la enfermedad del hígado graso no alcohólico (EHGNA), la asociación entre FIB4 y los hallazgos en la ecografía y las características clínicas de los pacientes con artritis psoriásica.

Material y métodos

Estudio transversal observacional de todos los pacientes con artritis psoriásica vistos de forma consecutiva en consulta desde 01/01/2020 hasta el 30/11/2020.

Resultados

De los 90 pacientes estudiados la prevalencia de EHGNA fue de 56,67%. EL FIB4 presenta asociación con la ecografía (p = 0.030), la ausencia de entesitis (p = 0.036) y la mayor duración de la enfermedad (Rho 0.213 p = 0.042). También con la presencia de hipertensión (p = 0.027) y el consumo de alcohol (p = 0.021). Sin embargo, el tratamiento biológico puede considerarse como un factor protector (p = 0.005). El FIB4 actúa como predictor de EHGNA con una sensibilidad 69.2% y especificidad 70.4%.

Conclusiones

La prevalencia de EHGNA fue superior a la población general. El índice FIB4 puede ser una herramienta válida en el despistaje de EHGNA en nuestra práctica clínica diaria.

Palabras clave:
Artritis
Enfermedad por hígado graso no alcohólico
EHGNA
Psoriasis
Artritis psoriásica
Inflamación
Enfermedad hepática
Cirrosis
Fibrosis
FIB4
Obesidad
Tratamiento
Inhibidores del anti-TNF
Hipertensión arterial
Diabetes mellitus tipo 2

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?